These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12372239)

  • 41. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics.
    Nightingale CH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):146S-149S. PubMed ID: 16305285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.
    Asín-Prieto E; Rodríguez-Gascón A; Isla A
    J Infect Chemother; 2015 May; 21(5):319-29. PubMed ID: 25737147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interpretative reading of the antibiogram--a semi-naïve Bayesian approach.
    Andreassen S; Zalounina A; Paul M; Sanden L; Leibovici L
    Artif Intell Med; 2015 Nov; 65(3):209-17. PubMed ID: 26323611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
    Nicolau DP
    J Infect Chemother; 2003 Dec; 9(4):292-6. PubMed ID: 14691648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic factors of antibiotic efficacy.
    Rotschafer JC; Zabinski RA; Walker KJ
    Pharmacotherapy; 1992; 12(6 Pt 2):64S-70S. PubMed ID: 1480502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.
    DeRyke CA; Lee SY; Kuti JL; Nicolau DP
    Drugs; 2006; 66(1):1-14. PubMed ID: 16398565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational dosing of antimicrobial drugs: animals versus humans.
    Lees P; Shojaee Aliabadi F
    Int J Antimicrob Agents; 2002 Apr; 19(4):269-84. PubMed ID: 11978498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Reading an antibiogram in the context of antimicrobial resistance].
    Roth-Müller A; Cherkaoui A; Andrey DO
    Rev Med Suisse; 2023 Apr; 19(822):720-725. PubMed ID: 37057853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment options in odontogenic infection.
    Maestre-Vera JR
    Med Oral Patol Oral Cir Bucal; 2004; 9 Suppl():25-31; 19-24. PubMed ID: 15580134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How predictive is PK/PD for antibacterial agents?
    Frimodt-Møller N
    Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?
    Theuretzbacher U
    Curr Opin Pharmacol; 2007 Oct; 7(5):498-504. PubMed ID: 17616438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Li RC; Zhu M; Schentag JJ
    Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy.
    Gumbo T
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):32-42. PubMed ID: 18175265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems.
    Cantón R; Oliver A; Alós JI; de Benito N; Bou G; Campos J; Calvo J; Canut A; Castillo J; Cercenado E; Domínguez MÁ; Fernández-Cuenca F; Guinea J; Larrosa N; Liñares J; López-Cerero L; López-Navas A; Marco F; Mirelis B; Moreno-Romo MÁ; Morosini MI; Navarro F; Oteo J; Pascual Á; Pérez-Trallero E; Pérez-Vázquez M; Soriano A; Torres C; Vila J; Martínez-Martínez L
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Apr; 38(4):182-187. PubMed ID: 30878313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice.
    Cohen R; Grimprel E
    Arch Pediatr; 2017 Dec; 24(12S):S6-S8. PubMed ID: 29290237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.